Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Radiotherapy Unit, Giovanni Paolo II Foundation, Catholic University of Sacred Heart, Campobasso, Italy.
Anticancer Res. 2019 Nov;39(11):6373-6378. doi: 10.21873/anticanres.13850.
BACKGROUND/AIM: Radiotherapy (RT) with adjuvant hormone therapy (HT) improves prognosis in prostate cancer (PC) patients. Gonadotrophin-releasing hormone agonist (GnRHa) with luteinizing hormone-releasing hormone (LH-RH) analogues is the standard HT. High-dose antiandrogen therapy also improves survival in patients with locally advanced PC. The aim of this study was to compare the results of patients treated with RT plus GnRHa and patients treated with RT plus bicalutamide.
Our institutional PC database was used to identify patients treated with definitive or postoperative RT +/- HT which were included in this study.
Three hundred and eighteen patients were retrospectively reviewed (median follow-up=56 months). Five-year biochemical relapse-free survival was 85.5% and 88.3% in patients treated with GnRHa and bicalutamide, respectively (p=0.712).
Bicalutamide may be offered as an adjuvant treatment to RT in patients who refuse GnRHa because of related side effects. Furthermore, our study justifies randomized trials comparing RT plus GnRHa and RT plus bicalutamide.
背景/目的：放疗 (RT) 联合辅助激素治疗 (HT) 可改善前列腺癌 (PC) 患者的预后。促性腺激素释放激素激动剂 (GnRHa) 联合黄体生成素释放激素 (LH-RH) 类似物是标准的 HT。高剂量抗雄激素治疗也可改善局部晚期 PC 患者的生存。本研究旨在比较接受 RT+GnRHa 治疗和 RT+bicalutamide 治疗的患者的结果。
我们使用机构性 PC 数据库来确定接受根治性或术后 RT +/- HT 治疗并纳入本研究的患者。
回顾性分析了 318 例患者（中位随访时间=56 个月）。接受 GnRHa 和 bicalutamide 治疗的患者 5 年生化无复发生存率分别为 85.5%和 88.3%（p=0.712）。
对于因相关副作用而拒绝 GnRHa 的患者，bicalutamide 可作为 RT 的辅助治疗。此外，我们的研究证明了比较 RT+GnRHa 和 RT+bicalutamide 的随机试验是合理的。
